Search

Your search keyword '"Hoem, Dag"' showing total 138 results
Start Over Author "Hoem, Dag" Publication Year Range Last 50 years
138 results on '"Hoem, Dag"'

1. Characterization of CEL-DUP2: Complete duplication of the carboxyl ester lipase gene is unlikely to influence risk of chronic pancreatitis

Author

Fjeld, Karianne, Masson, Emmanuelle, Lin, Jin-Huan, Michl, Patrick, Stokowy, Tomasz, Gravdal, Anny, El Jellas, Khadija, Steine, Solrun J., Hoem, Dag, Johansson, Bente B., Dalva, Monica, Ruffert, Claudia, Zou, Wen-Bin, Li, Zhao-Shen, Njølstad, Pål R., Chen, Jian-Min, Liao, Zhuan, Johansson, Stefan, Rosendahl, Jonas, Férec, Claude, and Molven, Anders

Published
2020
Full Text
View/download PDF

7. Diabetes and Pancreatic Exocrine Dysfunction Due to Mutations in the Carboxyl Ester Lipase Gene-Maturity Onset Diabetes of the Young (CEL-MODY): A PROTEIN MISFOLDING DISEASE

Author

Johansson, Bente B., Torsvik, Janniche, Bjørkhaug, Lise, Vesterhus, Mette, Ragvin, Anja, Tjora, Erling, Fjeld, Karianne, Hoem, Dag, Johansson, Stefan, Ræder, Helge, Lindquist, Susanne, Hernell, Olle, Cnop, Miriam, Saraste, Jaakko, Flatmark, Torgeir, Molven, Anders, and Njølstad, Pål R.

Published
2011
Full Text
View/download PDF

8. Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is Associated With Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin-Stimulated Duodenal Fluid

Author

Ræder, Helge, McAllister, Fiona E., Tjora, Erling, Bhatt, Shweta, Haldorsen, Ingfrid, Hu, Jiang, Willems, Stefan M., Vesterhus, Mette, El Ouaamari, Abdelfattah, Liu, Manway, Ræder, Maria B., Immervoll, Heike, Hoem, Dag, Dimcevski, Georg, Njølstad, Pål R., Molven, Anders, Gygi, Steven P., and Kulkarni, Rohit N.

Published
2014
Full Text
View/download PDF

9. Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid

Author

Raeder, Helge, McAllister, Fiona E., Tjora, Erling, Bhatt, Shweta, Haldorsen, Ingfrid, Hu, Jiang, Willems, Stefan M., Vesterhus, Mette, Ouaamari, Abdelfattah El, Liu, Manway, Raeder, Maria B., Immervoll, Heike, Hoem, Dag, Dimcevski, Georg, Njolstad, Pal R., Molven, Anders, Gygi, Steven P., and Kulkarni, Rohit N.

Subjects
Diabetes -- Genetic aspects -- Development and progression, Lipase -- Identification and classification -- Health aspects, Cellular signal transduction -- Research, Mitogen-activated protein kinases -- Properties, Health
Abstract

Carboxyl-ester lipase (CEL) maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes and pancreatic exocrine dysfunction due to mutations in the CEL gene encoding CEL. The pathogenic mechanism for diabetes development is unknown. Since CEL is expressed mainly in pancreatic acinar cells, we asked whether we could find structural pancreatic changes in CEL-MODY subjects during the course of diabetes development. Furthermore, we hypothesized that the diseased pancreas releases proteins that are detectable in pancreatic fluid and potentially reflect activation or inactivation of disease-specific pathways. We therefore investigated nondiabetic and diabetic CEL-mutation carriers by pancreatic imaging studies and secretin-stimulated duodenal juice sampling. The secretin-stimulated duodenal juice was studied using cytokine assays, mass spectrometry (MS) proteomics, and multiplexed MS-based measurement of kinase activities. We identified multiple pancreatic cysts in all eight diabetic mutation carriers but not in any of the four nondiabetic mutation carriers or the six healthy controls. Furthermore, we identified upregulated mitogen-activated protein kinase (MAPK) target proteins and MAPK-driven cytokines and increased MAPK activity in the secretin-stimulated duodenal juice. These findings show that subjects with CEL-MODY develop multiple pancreatic cysts by the time they develop diabetes and that upregulated MAPK signaling in the pancreatic secretome may reflect the pathophysiological development of pancreatic cysts and diabetes. Diabetes 2014;63:259-269 | DOI: 10.2337/db13-1012, Studies of patients with maturity-onset diabetes of the young (MODY) have provided important insight into disease mechanisms of pancreatic β-cell failure and diabetes development and also contributed to novel treatment [...]

Published
2014
Full Text
View/download PDF

11. Additional file 3: of Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma

Author

Choi, Man, MejlĂŚnder-Andersen, Eline, Manueldas, Sophia, Jellas, Khadija El, Solrun Steine, Tjensvoll, Kjersti, SĂŚtran, Hege, Knappskog, Stian, Hoem, Dag, NordgĂĽrd, Oddmund, Hovland, Randi, and Molven, Anders

Abstract

Table S3. Interpretation of all KRAS, TP53 and BRAF mutations observed in the study. (DOCX 37 kb)

Published
2019
Full Text
View/download PDF

12. Additional file 2: of Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma

Author

Choi, Man, MejlĂŚnder-Andersen, Eline, Manueldas, Sophia, Jellas, Khadija El, Solrun Steine, Tjensvoll, Kjersti, SĂŚtran, Hege, Knappskog, Stian, Hoem, Dag, NordgĂĽrd, Oddmund, Hovland, Randi, and Molven, Anders

Abstract

Table S2. List of genes and target regions covered by the TruSight Tumor 15 gene panel. (DOCX 19 kb)

Published
2019
Full Text
View/download PDF

13. Expression of the 'stem cell marker' CD133 in pancreas and pancreatic ductal adenocarcinomas

Author

Sakariassen Per, Hoem Dag, Immervoll Heike, Steffensen Ole, and Molven Anders

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background It has been suggested that a small population of cells with unique self-renewal properties and malignant potential exists in solid tumors. Such "cancer stem cells" have been isolated by flow cytometry, followed by xenograft studies of their tumor-initiating properties. A frequently used sorting marker in these experiments is the cell surface protein CD133 (prominin-1). The aim of this work was to examine the distribution of CD133 in pancreatic exocrine cancer. Methods Fifty-one cases of pancreatic ductal adenocarcinomas were clinically and histopathologically evaluated, and immunohistochemically investigated for expression of CD133, cytokeratin 19 and chromogranin A. The results were interpreted on the background of CD133 expression in normal pancreas and other normal and malignant human tissues. Results CD133 positivity could not be related to a specific embryonic layer of organ origin and was seen mainly at the apical/endoluminal surface of non-squamous, glandular epithelia and of malignant cells in ductal arrangement. Cytoplasmic CD133 staining was observed in some non-epithelial malignancies. In the pancreas, we found CD133 expressed on the apical membrane of ductal cells. In a small subset of ductal cells and in cells in centroacinar position, we also observed expression in the cytoplasm. Pancreatic ductal adenocarcinomas showed a varying degree of apical cell surface CD133 expression, and cytoplasmic staining in a few tumor cells was noted. There was no correlation between the level of CD133 expression and patient survival. Conclusion Neither in the pancreas nor in the other investigated organs can CD133 membrane expression alone be a criterion for "stemness". However, there was an interesting difference in subcellular localization with a minor cell population in normal and malignant pancreatic tissue showing cytoplasmic expression. Moreover, since CD133 was expressed in shed ductal cells of pancreatic tumors and was found on the surface of tumor cells in vessels, this molecule may have a potential as clinical marker in patients suffering from pancreatic cancer.

Published
2008
Full Text
View/download PDF

14. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma

Author

Choi, Man Hung, primary, Mejlænder-Andersen, Eline, additional, Manueldas, Sophia, additional, El Jellas, Khadija, additional, Steine, Solrun J., additional, Tjensvoll, Kjersti, additional, Sætran, Hege Aase, additional, Knappskog, Stian, additional, Hoem, Dag, additional, Nordgård, Oddmund, additional, Hovland, Randi, additional, and Molven, Anders, additional

Published
2019
Full Text
View/download PDF

15. Mutation analysis by deep sequencing of pancreatic juice in patients with pancreatic ductal adenocarcinoma

Author

Choi, Man Hung, primary, Mejlænder-Larsen, Eline, additional, Manueldas, Sophia, additional, El Jellas, Khadija, additional, Steine, Solrun J., additional, Tjensvoll, Kjersti, additional, Sætran, Hege Aase, additional, Knappskog, Stian, additional, Hoem, Dag, additional, Nordgård, Oddmund, additional, Hovland, Randi, additional, and Molven, Anders, additional

Published
2018
Full Text
View/download PDF

19. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial

Author

Labori, Knut Jørgen, primary, Lassen, Kristoffer, additional, Hoem, Dag, additional, Grønbech, Jon Erik, additional, Søreide, Jon Arne, additional, Mortensen, Kim, additional, Smaaland, Rune, additional, Sorbye, Halfdan, additional, Verbeke, Caroline, additional, and Dueland, Svein, additional

Published
2017
Full Text
View/download PDF

22. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling

Author

Pettersen, Kristine, primary, Andersen, Sonja, additional, Degen, Simone, additional, Tadini, Valentina, additional, Grosjean, Joël, additional, Hatakeyama, Shinji, additional, Tesfahun, Almaz N., additional, Moestue, Siver, additional, Kim, Jana, additional, Nonstad, Unni, additional, Romundstad, Pål R., additional, Skorpen, Frank, additional, Sørhaug, Sveinung, additional, Amundsen, Tore, additional, Grønberg, Bjørn H., additional, Strasser, Florian, additional, Stephens, Nathan, additional, Hoem, Dag, additional, Molven, Anders, additional, Kaasa, Stein, additional, Fearon, Kenneth, additional, Jacobi, Carsten, additional, and Bjørkøy, Geir, additional

Published
2017
Full Text
View/download PDF

25. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases

Author

Angelsen, Jon-Helge, Viste, Asgaut, Løes, Inger Marie, Eide, Geir Egil, Hoem, Dag, Sorbye, Halfdan, and Horn, Arild

Subjects
Perioperative chemotherapy, Oncology, Surgery, Overall survival, Post-recurrence survival, Sites of recurrence, Resection colorectal liver metastases, Time to recurrence
Abstract

Background: Despite progress in resection for colorectal liver metastases (CLM), the majority of patients experience recurrence. We aimed to evaluate factors influencing time to recurrence (TTR), treatment and post-recurrence survival (PRS) related to site of recurrence. Methods: This is a retrospective population-based cohort study (1998–2012) of consecutive patients without extrahepatic disease treated with resection for CLM in a referral centre. Results: A total of 311 patients underwent resection for CLM. After a median follow-up of 4.2 years (range 1.2–15.2), 209 (67.4 %) patients developed recurrence, hepatic 90, extrahepatic 59 and both 60. Median TTR was 14.0 months, and 5-year recurrence-free status was 25.7 %. Five- and 10-year overall survival (OS) was 38.8 and 22.0 %, respectively. Median OS was 45 months. A multivariate analysis displayed synchronous disease (hazard ratio (HR) 1.50), American Society of Anaesthesiologists (ASA) score (HR 1.40), increasing number (HR 1.24) and size of metastases (HR 1.08) to shorten TTR (all p

Published
2015

26. Percutaneous cholecystostomy in acutecholecystitis; a retrospective analysis of a largeseries of 104 patients

Author

Viste, Asgaut, Jensen, Dag Kjartan, Angelsen, Jon-Helge, and Hoem, Dag

Subjects
Complications, Cholecystitis, Cholecystostomy, Percutaneous
Abstract

Background: The purpose of this study was to evaluate the clinical course and possible benefit of a percutaneous cholecystostomy in patients with acute cholecystitis. Methods: Retrospective study of 104 patients with severe cholecystitis or cholecystitis not responding to antibiotic therapy treated with percutaneous drainage of the gall bladder (PC) during the period 2007 – 2013. Primary outcome was relief of cholecystitis, complications following the procedure and need for later cholecystectomy. Results: There were 57 men and 47 women with a median age of 73,5 years (range 22 – 96). 43% of the patients were ASA III or IV and 91% had cholecystitis Grade 2 or 3. About 60% of the patients had severe comorbidity (cardiovascular disease or active cancer). Drain insertion was successful in all but one patient and complications were mild, apart from two patients that needed percutaneous drainage of intraabdominal fluid collection due to bile leakage. The drain was left in place for 1 – 75 days (median 6,5). When evaluated clinically and by blood tests (CRP and white blood cell counts) we found resolution of symptoms in 101 patients (97,2%), whereas 2 patients had no obvious effect of drainage. Four patients died within 30 days, no deaths were related to the drainage procedure. Follow-up after drainage was median 12 months (range 0 – 78). During that time cholecystectomy was performed in 30 patients and 24 patients had died. Following cholecystectomy, two had died, both from cancer and more than one year after the operation. Conclusion: Patients with acute cholecystitis were promptly relieved from their symptoms following PC. There were only minor complications following the procedure and only about 30% of the patients had a later cholecystectomy. publishedVersion

Published
2015

27. Indre tarmbrokk

Author

Berle, Magnus, primary, Dahlslett, Kristine Hermansen, primary, Kavaliauskiene, Giedre, primary, and Hoem, Dag, primary

Published
2017
Full Text
View/download PDF

28. The carboxyl-ester lipase (CEL) gene – A risk factor for pancreatic cancer?

Author

Dalva, Monica, primary, Jellas, Khadija El, additional, Steine, Solrun, additional, Johansson, Bente Berg, additional, Ringdal, Monika, additional, Torsvik, Janniche, additional, Immervoll, Heike, additional, Hoem, Dag, additional, Laemmerhirt, Felix, additional, Simon, Peter, additional, Lerch, Markus M., additional, Johansson, Stefan, additional, Njølstad, Pål R., additional, Weiss, Frank Ulrich, additional, Molven, Anders, additional, and Fjeld, Karianne, additional

Published
2016
Full Text
View/download PDF

29. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma.

Author

Dimcevski, Georg Gjorgji, primary, Kotopouli, Spiros, additional, Bjåne, Tormod, additional, Hoem, Dag, additional, Schjött, Jan, additional, Gjertsen, Björn Tore, additional, Biermann, Martin, additional, Molven, Anders, additional, Sorbye, Halfdan, additional, McCormac, Emmet, additional, Postema, Michiel, additional, and Gilja, Odd Helge, additional

Published
2016
Full Text
View/download PDF

30. Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study

Author

Kotopoulis, Spiros, Dimcevski, Georg, Helge Gilja, Odd, Hoem, Dag, Postema, Michiel, Haukeland University Hospital, University of Bergen (UiB), and Department of Physics and Technology [Bergen] (UiB)

Subjects
ultrasound, [PHYS.PHYS.PHYS-MED-PH]Physics [physics]/Physics [physics]/Medical Physics [physics.med-ph], sonoporation, [SDV.CAN]Life Sciences [q-bio]/Cancer, chemotherapy, microbubbles
Abstract

International audience; Purpose: The purpose of this study was to investigate the ability and efficacy of inducing sonoporation in a clinical setting, using commercially available technology, to increase the patients’ quality of life and extend the low Eastern Cooperative Oncology Group performance grade; as a result increasing the overall survival in patients with pancreatic adenocarcinoma.Methods: Patients were treated using a customized configuration of a commercial clinical ultrasound scanner over a time period of 31.5 min following standard chemotherapy treatment with gemcitabine. SonoVue(R) ultrasound contrast agent was injected intravascularly during the treatment with the aim to induce sonoporation.Results: Using the authors’ custom acoustic settings, the authors’ patients were able to undergo an increased number of treatment cycles; from an average of 9 cycles, to an average of 16 cycles when comparing to a historical control group of 80 patients. In two out of five patients treated, the maximum tumor diameter was temporally decreased to 80 ± 5% and permanently to 70 ± 5% of their original size, while the other patients showed reduced growth. The authors also explain and characterize the settings and acoustic output obtained from a commercial clinical scanner used for combined ultrasound microbubble and chemotherapy treatment.Conclusions: It is possible to combine ultrasound, microbubbles, and chemotherapy in a clinical setting using commercially available clinical ultrasound scanners to increase the number of treatment cycles, prolonging the quality of life in patients with pancreatic adenocarcinoma compared to chemotherapy alone.

Published
2013
Full Text
View/download PDF

35. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase gene (CEL-MODY) : a protein misfolding disease

Author

Johansson, Bente B, Torsvik, Janniche, Gundersen, Lise, Vesterhus, Mette, Ragvin, Anja, Tjora, Erling, Fjeld, Karianne, Hoem, Dag, Johansson, Stefan, Rader, Helge, Lindquist, Susanne, Hernell, Olle, Cnop, Miriam, Saraste, Jaakko, Flatmark, Torgeir, Molven, Anders, Njolstad, Pal R, Johansson, Bente B, Torsvik, Janniche, Gundersen, Lise, Vesterhus, Mette, Ragvin, Anja, Tjora, Erling, Fjeld, Karianne, Hoem, Dag, Johansson, Stefan, Rader, Helge, Lindquist, Susanne, Hernell, Olle, Cnop, Miriam, Saraste, Jaakko, Flatmark, Torgeir, Molven, Anders, and Njolstad, Pal R

Abstract

CEL-MODY, diabetes with pancreatic lipomatosis and exocrine dysfunction, is due to dominant frame-shift mutations in the acinar cell carboxyl-ester lipase gene (CEL). As Cel knock-out mice do not express the phenotype and the mutant protein has an altered, intrinsically disordered tandem repeat domain, we hypothesized that the disease mechanism might involve a negative effect of the mutant protein. In silico analysis showed that the pI of the tandem repeat was markedly increased from pH 3.3 in wild-type (WT) to 11.8 in mutant (MUT) human CEL. By stably over-expressing CEL-WT and CEL-MUT in HEK293 cells, we found similar glycosylation, ubiquitination, constitutive secretion and quality control of the two proteins. The CEL-MUT protein demonstrated, however, a high propensity to form aggregates found intracellularly and extracellularly. Different physico-chemical properties of the intrinsically disordered tandem repeat domains of WT and MUT proteins may contribute to different short-range and long-range interactions with the globular core domain and other macromolecules, including cell membranes. Thus, we propose that CEL-MODY is a protein misfolding disease caused by a negative gain-of-function effect of the mutant proteins in pancreatic tissues.

Published
2011
Full Text
View/download PDF

36. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease.

Author

Johansson, B., Torsvik, Janniche, Bjørkhaug, Lise, Vesterhus, Mette, Ragvin, Anja, Tjora, Erling, Fjeld, Karianne, Hoem, Dag, Johansson, Stefan, Ræder, Helge, Lindquist, S, Hernell, Olle, Cnop, Miriam, Saraste, Jaakko, Flatmark, Torgeir, Molven, Anders, Njølstad, Pal R., Johansson, B., Torsvik, Janniche, Bjørkhaug, Lise, Vesterhus, Mette, Ragvin, Anja, Tjora, Erling, Fjeld, Karianne, Hoem, Dag, Johansson, Stefan, Ræder, Helge, Lindquist, S, Hernell, Olle, Cnop, Miriam, Saraste, Jaakko, Flatmark, Torgeir, Molven, Anders, and Njølstad, Pal R.

Abstract

CEL-maturity onset diabetes of the young (MODY), diabetes with pancreatic lipomatosis and exocrine dysfunction, is due to dominant frameshift mutations in the acinar cell carboxyl ester lipase gene (CEL). As Cel knock-out mice do not express the phenotype and the mutant protein has an altered and intrinsically disordered tandem repeat domain, we hypothesized that the disease mechanism might involve a negative effect of the mutant protein. In silico analysis showed that the pI of the tandem repeat was markedly increased from pH 3.3 in wild-type (WT) to 11.8 in mutant (MUT) human CEL. By stably overexpressing CEL-WT and CEL-MUT in HEK293 cells, we found similar glycosylation, ubiquitination, constitutive secretion, and quality control of the two proteins. The CEL-MUT protein demonstrated, however, a high propensity to form aggregates found intracellularly and extracellularly. Different physicochemical properties of the intrinsically disordered tandem repeat domains of WT and MUT proteins may contribute to different short and long range interactions with the globular core domain and other macromolecules, including cell membranes. Thus, we propose that CEL-MODY is a protein misfolding disease caused by a negative gain-of-function effect of the mutant proteins in pancreatic tissues., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2011

37. Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is Associated With Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin-Stimulated Duodenal Fluid

Author

Ræder, Helge, primary, McAllister, Fiona E., additional, Tjora, Erling, additional, Bhatt, Shweta, additional, Haldorsen, Ingfrid, additional, Hu, Jiang, additional, Willems, Stefan M., additional, Vesterhus, Mette, additional, El Ouaamari, Abdelfattah, additional, Liu, Manway, additional, Ræder, Maria B., additional, Immervoll, Heike, additional, Hoem, Dag, additional, Dimcevski, Georg, additional, Njølstad, Pål R., additional, Molven, Anders, additional, Gygi, Steven P., additional, and Kulkarni, Rohit N., additional

Published
2013
Full Text
View/download PDF

48. Endoscopic Sphincterotomy in Acute Gallstone Pancreatitis: A Prospective Study of the Late Outcome.

Author

Gislason, Hjörtur, Vetrhus, Morten, Horn, Arild, Hoem, Dag, Söndenaa, Karl, Søreide, Odd, Viste, Asgaut, and Andrén-Sandberg, Åke

Subjects
PANCREATITIS, GALLSTONES
Abstract

Objective: To describe the outcome after acute biliary pancreatitis in patients treated during the acute attack by endoscopic sphincterotomy without cholecystectomy. Design: Prospective observational study. Setting: University hospital, Norway. Subjects: 130 patients with gallstones and acute pancreatitis. In 62 patients with common bile duct stones the bile duct was cleared by sphincterotomy and stone extraction. The remaining 68 patients had prophylactic sphincterotomy. Cholecystectomy was not planned later. Main outcome measures: Incidence of recurrent acute pancreatitis and need for cholecystectomy. Results: 21 patients were dead or not available for the follow-up. Consequently 109 patients were followed-up for a median of 39 months (range 23-62). One patient had recurrent pancreatitis. 20 patients had a cholecystectomy later for symptoms related to gallstone disease. Of the rest, 25 patients had moderate or mild gallstone-related symptoms. There was no difference in gallstone-related symptoms between those who had had stones in the bile duct and those who had not. 63 patients had no symptoms related to gallstones. Conclusion: Endoscopic sphincterotomy during or immediately after acute gallstone pancreatitis resulted in half the patients being free of symptoms during the next three years. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

49. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAFand EGFRgenes

Author

Immervoll, Heike, Hoem, Dag, Kugarajh, Kalaiarasy, Steine, Solrun, and Molven, Anders

Abstract

The vast majority of tumors of the pancreas are ductal adenocarcinomas. This cancer type has an extremely poor prognosis and in many Western countries, it represents the fifth leading cause of cancer-related death. Pancreatic ductal adenocarcinomas exhibit the highest incidence of activating KRAS(Ki-Ras) mutations observed in any human cancer. It was therefore of interest to examine how this pattern would relate to mutations in the BRAFand EGFRgenes, which are involved in the same signaling pathway as KRAS. We screened a series of 43 formalin-fixed, paraffin-embedded ductal adenocarcinomas of the pancreas. When DNA was extracted from whole tissue sections, KRAScodon 12 mutations were detected in 67% of the tumors. When cancerous ducts were isolated by laser-assisted microdissection, 91% were positive for KRASmutations. Although it did not reach statistical significance, there was a trend in our material that survival after diagnosis varied according to KRASmutation subtype, GTT-positive patients having the best prognosis. No alterations in BRAFexons 11 and 15 or in EGFRexons 18–21 were detected in KRAS-positive or KRAS-negative cases. We therefore conclude that the BRAFand EGFRmutations commonly seen in a variety of human cancers are generally absent from pancreatic ductal adenocarcinomas. Apparently, these tumors depend on no more than one genetic hit in the EGFR-RAS-RAF signaling pathway.The vast majority of tumors of the pancreas are ductal adenocarcinomas. This cancer type has an extremely poor prognosis and in many Western countries, it represents the fifth leading cause of cancer-related death. Pancreatic ductal adenocarcinomas exhibit the highest incidence of activating KRAS(Ki-Ras) mutations observed in any human cancer. It was therefore of interest to examine how this pattern would relate to mutations in the BRAFand EGFRgenes, which are involved in the same signaling pathway as KRAS. We screened a series of 43 formalin-fixed, paraffin-embedded ductal adenocarcinomas of the pancreas. When DNA was extracted from whole tissue sections, KRAScodon 12 mutations were detected in 67% of the tumors. When cancerous ducts were isolated by laser-assisted microdissection, 91% were positive for KRASmutations. Although it did not reach statistical significance, there was a trend in our material that survival after diagnosis varied according to KRASmutation subtype, GTT-positive patients having the best prognosis. No alterations in BRAFexons 11 and 15 or in EGFRexons 18–21 were detected in KRAS-positive or KRAS-negative cases. We therefore conclude that the BRAFand EGFRmutations commonly seen in a variety of human cancers are generally absent from pancreatic ductal adenocarcinomas. Apparently, these tumors depend on no more than one genetic hit in the EGFR-RAS-RAF signaling pathway.

Published
2006
Full Text
View/download PDF

50. Salvage of a dislodged hepaticogastrostomy stent in the peritoneum with NOTES.

Author

Khanh Do-Cong Pham, Hoem, Dag, Horn, Arild, Dimcevski, Georg G., and Pham, Khanh Do-Cong

Subjects
*PERITONEUM surgery, *NATURAL orifice transluminal endoscopic surgery, *LUNG cancer, *STOMACH surgery, *ENDOSCOPIC ultrasonography, *ENDOSCOPY, *PERITONEUM, *SURGICAL stents, *SURGICAL anastomosis, BILE duct surgery
Abstract

The article presents a case study of a 68-year-old man diagnosed with lung cancer and underwent natural orifice transluminal endoscopic surgery (NOTES) procedure to rescue a misplaced hepaticogastrostomy stent.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results